Latest news
TGTX Stock Jumps 5% On Positive Early Data For At-Home BRIUMVI In Muscle Disease - StocktwitsStocktwits · Fri, 07 Aug 2026 02:04:14 GMTTG Therapeutics (TGTX) Looks Fairly Valued After Raised 2026 Guidance And Mixed Q2 Earnings - simplywall.stsimplywall.st · Thu, 06 Aug 2026 08:14:06 GMTTG Therapeutics (NASDAQ: TGTX) grows 2026 revenue to $445 million - Stock TitanStock Titan · Wed, 05 Aug 2026 21:01:51 GMTTG Therapeutics: BRIUMVI Revenue Jumps 64% To $227.7 Million - Pulse 2.0Pulse 2.0 · Wed, 05 Aug 2026 16:48:41 GMTTG Therapeutics' BRIUMVI sales jump 64% YoY, bo... - PluangPluang · Mon, 03 Aug 2026 21:54:27 GMTTGTX: Strong revenue growth and profitability driven by BRIUMVI, with robust liquidity and pipeline progress - TradingViewTradingView · Mon, 03 Aug 2026 21:02:19 GMTTGTX: Record BRIUMVI growth and raised guidance highlight a strong quarter and expanding franchise - TradingViewTradingView · Mon, 03 Aug 2026 14:37:33 GMTTG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance - TG TherapeuticsTG Therapeutics · Mon, 03 Aug 2026 14:18:06 GMT